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ABSTRACT
The lower respiratory regions of the lung boast over 900 million alveoli with a
combined 85 m2 of surface area of near direct access to the bloodstream. Within the last
century the immense potential of the deep lung as a site for the delivery of drugs has
begun to be exploited and today pulmonary delivery of aerosolized therapeutic is
commonplace. High inter- and intra-patient variability in dosing continues to plague the
industry. Currently, only a few researchers are actively seeking to mitigate the sources of
physiological variability. This study seeks to prove that careful selection of a particle size
distribution can improve inhaler performance and reliability over a range age and
inhalation velocity. In this study, lung morphometry and flow rate were considered to be
the uncontrollable sources of inter- and intra-patient variability. Three populations
representing different lung geometries were explored: adults aged 14 to 21 years old,
children aged 1 to 9 years old and adults with severe lung remodeling. The range of flow
rates considered was customized to the population based upon normal to severe asthmatic
breath rates specific to that age group. Classical equations predicting deposition were
utilized in conjunction with cadaver data to establish particle deposition behavior as a
function of age and velocity. The coefficient of variation within an age group and over
the range of velocities was minimized to obtain an optimized particle size distribution.
This investigation demonstrated that current devices favor the healthy adult leaving
ii

critical populations such as infants and children with extremely poor deposition
efficiency. The optimal particle size distributions for the adult, adult with airway
remodeling and child cohorts were monodispersed with mean diameters of 3.6, 2.8 and
1.2 µm respectively. These results demonstrate that one particle size distribution cannot
be used to treat the entire population of inhaler users and greater attention should be paid
to selecting an appropriate size distribution.
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NOMENCLATURE
Ps – Fraction of particles deposited by
sedimentation

Cc – Cunningham slip correction factor
D – Airway diameter

RH – Relative humidity

d – Particle diameter
Dd – Diffusion coefficient

ri – Particle radius of the ith particle
diameter

FRC – Functional residual capacity

Stk – Stokes number

FSI – Fluid-solid interaction

T – Temperature (37°C)

Fvi – Fraction of the adjusted cumulative
volume available for deposition
calculations

TLC – Total lung capacity

g – Gravitational force (9.81 m/s2)

Uo – Flow velocity

k – Boltzmann’s constant(1.38x10-23
J•K-1)

Vp – Volume of particles

TV – Tidal volume

vsettleing – Settling velocity

L – Airway length

Vtotal – Total adjusted cumulative
volume

Ndep – Total number of particles
deposited

xd – Root mean square displacement

NT – Total number of particles

xs – Settling distance

P – Fraction of particles deposited for all
deposition mechanisms

α – Bifurcation angle
θ – Posture angle

Pd – Fraction of particle deposited by
diffusion

λ – Mean free path of air

Pi,CL – Fraction of particles deposited by
impaction using Chan & Lippman
equation

ρf – Fluid density
ρp – Particle density

Pi,CY – Fraction of particles deposited by
impaction using Cai & Yu equation

µ f - Fluid viscosity

Pi,diameter – Fraction of total particles (NT)
of the ith particle diameter

x

CHAPTER ONE: INTRODUCTION
Background
Administering therapeutics via the respiratory tract has many distinct advantages
over other delivery routes. First, when used for the treatment of diseases of the lung,
direct application yields rapid response, reduces the dose required and lessens the risk of
negative side effects. Also, the branching nature of the lung, with 24 generations, 900
million alveoli, and a surface area upwards of 85 m2 with only 0.2-0.6 µm between the
airway the blood stream, all of which make the respiratory zone ideal for drug absorption
into the blood stream [1]. Direct access to the blood stream via respiration into the lungs
allows drugs to bypass the gastrointestinal tract – a huge advantage over orally
administered medicine in that the potential loss or degradation of a therapeutic due the
digestive system enzymes is avoided. While the blood stream can also be directly
accessed by delivering drugs intravenously, this route can be painful and patient
compliance is often low as a result. As there is no pain associated with the inhalation of
aerosolized therapeutics, patient compliance is much better than with intravenous
delivery. Furthermore, the delivery would not need to be done by a trained medical
professional as is usually the case for intravenous delivery. Even though there is this
immense potential for pulmonary delivery, the major downfall in delivery devices today
is efficiency.

1

Drug deposition efficiency to patients’ lungs has increased recently from <20% to
>50% of the delivered dose as device technology has matured to control particle size,
distribution and injection velocity. Driving this improvement is the fact that, despite the
presence of at least sixty-five aerosol devices already on the market [2], there is still a
significant and growing need for more patient-operation-independent devices that provide
the reliable and repeatable drug release that pulmonary delivery affords [3]. If this
limitation can be overcome, the potential of the lungs as a drug administration route
could be boundless.
It is important to understand how drugs are delivered to lung before one can seek
to improve delivery efficiency. Currently, drugs are delivered to the respiratory tract by
aerosolizing the therapeutic agents as dry bulk powders, emulsions, solutions, or solidparticle suspensions [1]. These formulations can then be inhaled by the patient. The drug
then either treats the lung topically or is absorbed into the blood stream. The
aerosolization devices most commonly used are: (1) dry-power inhalers (DPI), (2)
nebulizers and (3) propellant driven metered dose inhalers (pMDI).
Dry-power inhalers generally utilize the inspiratory flow of the patient to
discharge and mix the dry powder into the air stream for drug delivery (Figure 1.1).
However, DPI flow-rate-independent devices that use pressurized air to disperse the
drugs also exist. [1] It is important to note here that although dispersion in the latter DPI
device is flow-rate-independent, the deposition within the lung itself is still highly flowrate-dependent, so the breath rate of the user still affects deposition.
2

Jet nebulizers produce liquid droplet aerosols using high velocity air to shear
droplets from a bulk liquid which produces small particles between 1 and 5 µm in
diameter (Figure 1.1). The generated aerosol is then allowed to circulate within a
reservoir prior to inhalation by the patient. Other devices exist that produce liquid
aerosol droplets between 50 and 200 µm by forcing the liquid through a small orifice, but
this range of diameters is too large to make it into the lung therefore those devices are
used exclusively for oral and nasal deposition [1].
A pMDI inhaler creates aerosols from liquid emulsions, solutes or micronized
power within a propellant by releasing a known volume of pressured therapeutic particle
mixture suspended in a propellant (Figure 1.1) [1].
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Figure 1.1: Schematics of Commercialized Device Operation.
Top left: Metered dose inhaler (http://www.asthma.ca/adults/treatment/meteredDoseInhaler.php)
Top right: Dry-power inhaler (http://www.asthmameds.ca/diskus.php)
Bottom center: Jet nebulizer (http://www.medscape.com/viewarticle/579507_4)

Where therapeutic particles deposit on many variables including tongue position,
injection velocity, injection angle, airway elasticity, particle properties, physiological
dimensions and flow rate.
The position of the tongue contributes significantly to the variation in the
geometry of the upper airway, and most importantly the cross-sectional area of the oral
cavity [4]. As the airway geometry in the oral cavity is influenced by the position of the
tongue, the number of particles that deposit will be affected. Consequently, the deposition
4

in the lower regions of the lung will also be affected. Tongue position can also affect the
flow in the oral cavity with respect to the injection angle of the aerosol, as shown by the
studies conducted by Fadl et al [5]. They revealed that when the aerosol jet is angled
towards the tongue, boundary layers develop and the flow behaves similar to that of flow
over a plate. This asymmetric flow profile gives rise to larger deposition at the back of
the throat because the jet velocity farther away from the tongue is not slowed and the
particles cannot follow the streamlines down into the lower airways. Fadl et al argue that
an optimum angle can be found which will foster a more “symmetrical” velocity profile
causing the jet to slow down both at the interface with the tongue and with the roof of the
mouth therefore maximizing penetration into the lower airways [5].
The inspiratory and injection flow rates are also key factors of deposition in many
stages of the therapeutic delivery process. For delivery devices such as the DPI which
rely on the user’s inspiration flow rate to disperse the therapeutic, inspiration with too
low of a breath rate could result in little to no therapeutic being dispensed from the
inhaler. In fact, insufficient flow rates for dispersion of the dose are quite common
especially in users over 60 years old [6].A study showed that, depending on which DPI
inhaler is being used, as much as 38.9% of users between 18 and 59 years old and 66% of
users over 60 were unable to produce sufficient airflow to properly dispense the dose [6].
At the opposite end of the spectrum, pMDIs deliver a dose within a very short time,
approximately 0.1 second, which means that the particles are injected at very high
velocities. At high velocities particles have more inertia and have a tendency impact at
the back of the throat where there is a change in flow direction down into the trachea [1].
5

Once the aerosol spray makes it past the upper airways and into the trachea, the
mechanism by which a particle deposits in the lung depends largely on the properties of
the particle, the geometry of the lung and the properties of the fluid carrying the particle.
If a particle is of a size and density such that it has enough inertial energy to leave the
stream lines when there is a change in direction of the flow and its stopping distance is
greater than or equal to its distance from the wall, it will collide with the wall of the lung
and thus deposit via inertial impact. When a particle’s diameter is less than or equal to the
mean free path of the fluid, random motion results from repeated particle collision with
the neighboring fluid molecules. Given sufficient time this random motion could
eventually cause a particle to collide with the lung wall and deposit. If this diffusive time
is less than the residence time of the particle within the tube then it is said to have been
deposited by Brownian motion. Finally, gravitational forces will act on the particle.
Gravitational settling times will be a function of tube angle in relation to gravity and tube
diameter. If the settling time is less than the residence time for the particle then
deposition by sedimentation occurs. Charged particles can also experience electrostatic
forces but because of the humid environment of the lung, inhaled particles are assumed to
be charge neutral. A visual representation of the mechanisms of deposition considered in
this study is shown in Figure 1.2 below.
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Figure 1.2: Mechanisms of Deposition in the Lung. [This image was modified from and image found at
http://www.coheadquarters.com/PennLibr/MyPhysiology/lect6p/lect6.02.htm]

Since the efficiency and efficacy of pulmonary therapeutic delivery is affected by so
many different variables, control and mitigation techniques are constantly being
researched, engineered and commercialized. The position of the tongue and the angle at
which the aerosol jet is administered can be controlled simply by using a suitable
mouthpiece attached to the delivery device.
Flow rates, on the other hand, are significantly more complex. Currently, injection
velocity is commonly reduced in pMDI inhalers using a device called a ‘spacer’ which
can come in many shapes and sizes from a simple tube to a 750 mL holding chamber one
of which is pictured below in Figure 1.3. As the aerosol jet enters the spacer, the jet is
slowed down by the resistance in the air and the particles are allowed time to evaporate.
This combination results in a slower moving spray made up of smaller particles which
increases the likelihood that they will make it into the trachea without impacting at the
back of the throat and reduces the need for coordination between actuation and inhalation
7

[7]. A device called a “Soft Mist” inhaler has recently been developed to also mitigate the
flow rate and coordination issue addressed by the spacers as discussed previously. The
“soft mist” inhaler, pictured below in FIGURE 1.3, forces a metered dose of therapeutic
through a specifically engineered nozzle to produce an aerosol that has a lower injection
velocity and a much longer cloud generation time, 1.5 s, than the pMDI counterpart
without the bulky spacer [8]. For the inspiratory flow rate requirements of a DPI inhaler,
a device called the “Novolizer” was developed which gives the user feedback as they use
the device (Figure 1.3). A Novolizer has a display window with an indicator that remains
green until the user generates sufficient inspiratory flow; it then turns red indicating that
the drug has been delivered. This device also has a trigger flow valve that only releases
the dose when the proper flow rate is achieved, so the user can be sure that a proper dose
was administered [9].
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Figure 1.3: Commercialized Injection Velocity Control D
Devices.
Top left: Spacer (http://www.asthma.ca/adults/treatment/spacers.php
http://www.asthma.ca/adults/treatment/spacers.php). Top right: Soft Mist inhaler
(http://www.respimat.com/functions_and_use/howitworks.html
http://www.respimat.com/functions_and_use/howitworks.html). Bottom: Novolizer
(http://www.novolizer.com/wms/novolizer/inhaler/correctinhalation
http://www.novolizer.com/wms/novolizer/inhaler/correctinhalation).
).

The remaining variables, then, are those which affect deposition once the spray makes
it into the trachea namely: particle proper
properties,
ties, flow properties, and airway geometry.
Predicting deposition in the deep lung becomes complex at this point because neither a
person’s airway geometry nor the rate at which they breathe can be considered
controllable variables. The unpredictable natur
naturee of lower airways makes it nearly
impossible for physicians to know how much therapeutic their patients are actually
receiving. This means that over
over- and under-dosing
dosing is a frequent occurrence in the inhaled
pharmaceutical world.
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Study Objective
The objective of this study is to use the characteristics of an aerosol spray to reduce the
variability in deposition caused by the patient-to-patient fluctuations in airway geometry
and inspiratory breath rate. The International Pharmaceutical Aerosol Consortium on
Regulation and Science (IPAC-RS) has suggested that particle size distributions be a
focus of study for inhaled pharmaceutical bioavailability [3]. Also, no standards have
been set with for a minimum of delivered particles [3], so we hypothesize that a
distribution of particles exists which will minimize the variability in deposition in order
to provide more reliable patient dosing. Even if the reduced variability comes at the
expense of the total volume deposited, we hope that reliable deposition will aid in the
proper dosing of patients.
Other research exploring particle size distribution in relation to deposition does not
seek out an optimum distribution, but instead just reports the effects different particle
sizes have on deposition or lung response. For instance, a study done by Johnson et al.
revealed that bronchodilation response to salbutamol was significantly better when 3.3
µm diameter particles were used as opposed to a larger 7.7 µm particle. This suggests the
particle diameter should be selected to target specific areas of the lung where the drug
can be most effective [2]. Another study done by Rees et al. [10]explored the clinical
effect of three different particle size ranges (<5 µm, 5-10 µm and 10-15 µm) on
asthmatics and found that the smallest particles performed the best because they penetrate
the restricting airways better than larger particles. [2]. Zanen et al. [11] investigated
three particle sizes in the range ≤5 µm (1.5 µm , 2.8 µm and 5 µm) and found that if the
10

particles are too big they do not penetrate deep enough into the lung, but if they are too
small they can deposit too deeply into the fringes of the lung and therefore have no
therapeutic effect [2]. This suggests that particle size should be chosen with respect to a
patient’s disease state. In their study, Zanen et al.[12] found that a particle size of 2.8 µm
is most effective for patients with mild to moderate asthma, but for severe asthma treated
with β2 agonist or anticholinergic a diameter closer to 3 µm would be best [2]. Each of
these studies shows that particle size is critical when treating diseases of the lung, but
they only talk about optimum diameters with respect to targeting specific diseases on
specific types of patients. A more encompassing approach to particle size optimization
needs to be taken to economically address the needs of the population.
The current work will explore deposition reliability in the deep lung using both
empirical and derived probabilistic equations for deposition in a formal optimization
scripted in MatLab. We will not address sources of variability that can be managed using
commercial techniques like injection velocity and angle. Instead, the focus will be on
engineering a polydisperse spray that minimizes variability from the uncontrollable,
physiological sources: lung morphometry and flow rate. A baseline of current PDI and
pMDI reliability performance was set and four particle size distributions were tested in
the optimization routine to gauge relative performance for a 21-year-old male over a
range of flow rates from 10 (healthy) to 30 (severe asthmatic) L/min. The effect of
different deposition equations on the optimization is also explored. From here, two
distributions were chosen and the optimization was run with the addition of the varied
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lung geometries of an 18-, 14.08- and 14-year-old and again for four children’s lung
geometries between 3 months and 3 years old.
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CHAPTER TWO: METHODS
To optimize a polydisperse spray size distribution entering the upper airways of a
human lung that results in the least variability of deposited drug dose to the lower
lung regardless of human physiology or health state requires calculation of particle
deposition by impaction, sedimentation and diffusion in every generation or branch of
a human lung. These deposition mechanisms are dependent on airway lengths and
diameters, which are functions of size, weight or age as well as lung volumetric flow
rates linked to health state and particle characteristics.

Assumptions
For deposition correlations used in this study to be valid, certain assumptions
about the particles, the lung morphometry and the flow must be made. First, oral
cavity (i.e., tongue position), injection angle, and breath velocity aligning to injection
velocity is assumed to be controllable by the device. This means that deposition
occuring in the extrathoracic region is not taken into consideration and deposition is
only evaluated from the trachea to the deep lung. Second, the applicable particle size
range (diameter = 1 to 7 m) was drawn from literature and it is consistent with what
others have found to consistently make it through the oral cavity and larynx. This also
means that the section of the respiratory system that includes the larynx is not
modeled. This assumption is not ideal as the larynx controls what enters the trachea,
13

but accurate modeling of the flapping behavior of this portion of the respiratory tract,
requires a fluid-solid interaction model which is outside the scope of the current
study.
The particles are assumed to be water with a density, ρp, of 1000 kg/m3 and a
viscosity, µ p, of 8.90E−4 kg/m-s. A constant dose of 1.2 µL of particles is
homogenously distributed throughout the inhaled volume. This dose was chosen
based upon guidelines put forth by the FDA which state that in a 25 to 100 µL
volume, only a few micrograms to a few milligrams of active ingredients should be
present. Using water for the particle properties is also acceptable. Not only are most
pharmaceutical densities near that of water, but the diameter of the particle in this
study would then be the aerodynamic diameter for particles of different densities.
Pharmaceutical companies often describe their particles in terms of their aerodynamic
diameter, which is the diameter of a water droplet that has the same settling velocity
as the particle in question. In other words, a water droplet of size dae behaves the
same, aerodynamically, as a corresponding particle of diameter, d.
The fluid being used is 99.5% RH air [13] with a density, ρf, of 1.112 kg/m3 and a
viscosity, µ f , of 1.843E-5 kg/m·s which is representative of the conditions found in
the lung. The equations used assume that the particles are spherical and have a
density much larger than the fluid. This is a valid assumption given the 1000 kg/m3
particle density, ρp, and the 1.112 kg/m3 fluid density. Other properties used include
the mean free path, λ, of 0.072 µm at 37ºC and 1 atm, the Boltzmann’s constant, k, of
14

(1.38x10-23 J•K-1), and the temperature, T, of 37 ºC. The flow is considered to be
incompressible and hygroscopic affects to the particles are ignored.

Deposition Calculations
To approximate deposition, expressions predicting the probability that a
particle will deposit via each of the mechanisms discussed in Chapter 1 need to be
utilized. Throughout the last century, scientists and mathematicians have solved
fundamental fluid mechanics equations and fit experimental data to derive these
expressions for deposition by diffusion (Brownian motion), sedimentation and
impaction.
Diffusion/Brownian Motion
Since diffusion is motion due to multiple collisions with the molecules of
the fluid, the exact movement of the particle is not easily calculated mathematically.
The general motion of the particles can be approximated by solving the convectiondiffusion equation. This equation was solved for an aerosol concentration assuming
plug flow by Buchwald (1921), and Fuchs (1964), to come up with the following
equation for deposition resulting from Brownian diffusion [13]:


  1  4 



1


 

This equation requires an approximation of λm which is provided by Abramowitz
and Stegun (1981) [13]:
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Because the previous equations would need to be evaluated using
thousands of terms to be fully accurate, an empirical approximation was needed. This
approximation states that for values of ∆ greater than 0.16853 the probability of
deposition by diffusion can be taken to be one, but if ∆ is less than or equal to
0.16853, the following equation can be used to calculate Pd [13]:
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The equation above calculates deposition within 2% of the actual solution
discussed earlier for 10-9 < ∆ <0.3. This range is acceptable given the ∆’s calculated
in this study. This being said, Brownian motion is sometimes insignificant in
comparison to sedimentation. To characterize particle movement due to random
collisions with molecules, the root mean square displacement, xd, must be calculated
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which is a function of the diffusion coefficient, Dd, and the time spent in a given
generation, t (Finlay,2001).
D  E2F G
where,
F 
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A ratio of the displacement, xd, to the settling distance, xs, defined below, can then
indicate whether or not diffusion can be ignored. If the ratio is less than 0.1 the deposition
by diffusion is negligible.
DH  νHJKKLMNO G
Sedimentation
Sedimentation, as discussed in Chapter 1, is deposition resulting from gravitational
forces acting on a particle. For this reason, deposition by sedimentation can be calculated
exactly using gravitational and fluid equations. Heyder (1975) derived an expression for
deposition of particles by sedimentation for plug flow in a circular tube taking into
account the posture angle, θ. In this case the posture angle was taken to be 38.24 ° which
is an accepted value in lung modeling [13].
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Impaction

Due to the complexity of the lung geometry and flow in the lung, many empirical
correlations must be made to model deposition in the lung by impaction. Because
these equations were derived from observations, it was necessary to compare
calculated deposition to experimental results. The branching characteristics of the
lung made it necessary to find experimental deposition data that incorporated
bifurcation. The data used for comparison were those from cast data taken by Chan
and Lippman.(1980).The deposition efficiency was plotted against the Stokes number
of the parent generation and therefore the results could easily be compared to the
deposition efficiency and Stokes numbers calculated using the various impaction
equations. The Stokes number is the ratio of the inertial forces of the particle to the
drag forces acting on the particle and as such characterizes the movement of the
particle through the airway. The results of this evaluation can be seen below in Figure
2.1.
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Figure 2.1: Deposition Efficiency Calculated by Impaction Deposition Models
and Measured Experimentally as a function of the Stokes Number.

The Stokes numbers in this study are between zero and 0.3. Since the range is so
large and none of the correlations match perfectly, both the Uniform Cai and Yu
correlation and the Chan and Lippmann correlation were then evaluated and
compared. Those two were chosen because they represent an under and over
estimation of deposition respectively. The Cai and Yu uniform flow was chosen to
remain consistent with the diffusion and sedimentation equations. The Chan and
Lippmann equation is a function of the Stokes number as can be seen below:
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The Cai and Yu equation assuming uniform flow depends on the stokes number
as well, but it must also take into account the diameter ratio of the daughter to parent
generation, R/Ro, and the bifurcation angle, α.
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For the purposes of this lung model, the bifurcation angle, α, was taken to be
32.1° based upon the measurements taken from 100 patients by Haskin and Goodman
(1982).
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Total Deposition

Finally, these expressions for the fraction of particles depositing by each
mechanism need to be combined to model the total deposition. If all modes of
deposition are considered the following equation determines the total probability of
deposition.
  M ]  H ]   ] ⁄]
The value of p in the exponents was taken to be 2 as recommended by the
International Commission on Radiological Protection (ICRP). If diffusion can be
ignored because it significance as a deposition mechanism is dwarfed by that of
sedimentation, this simpler expression can be used:
  M  H  M H
Fixing the Volume of Particles
Since this study seeks to explore the effect of a polydispersed spray on the volume
of particles deposited in the deep lung, it is necessary to have the total dose remain
constant while only changing the concentration of particles of a certain diameter. To
maintain a constant dose, the following relation was used to determine the total
number of particles within a polydispersed spray:
jk 

lm

4
∑NM f h .,M M,Mo
3

JKJp

Where NT is the total number of particles of a particular diameter, Vp is the total
fixed volume, ri is the radius of the particle and Pi,diameter is the fraction of particles
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that will be of diameter, di, based on a chosen distribution, which will be discussed
later.
Adjusting the Inhaled Volume
In this model, particles are homogeneously distributed throughout the volume.
Because the entire volume won’t make it to the deepest parts of the lung, particles
need to be tracked in relation to their position in the inhaled tidal volume. To do this,
a calculation is performed at each generation which determines the remaining volume
available for deposition. The equation used for this calculation is:
qrs  1 

∑ lM 
lkgKoL

where FVi is the fraction of the adjusted cumulative volume still available, VTotal is
the total adjusted cumulative volume, and ∑Vi-1 is the sum of the adjusted volumes
above that generation.

This volume fraction was then combined with the total

probability of deposition, P, and the total number of particles, NT, using the equation
below to determine the total number of particles deposited of the diameter in
question.
jJ]  qrs jk 
Lung Morphometry Data
Lung Morphometry data from Ménache, et al. (2008) was used because it has data
for various ages, both male and female, and all of the data was taken using the same
technique. This data can be found in Appendix A. Demographic information
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concerning the population represented in cast data is summarized in Table 2.1 and
physiological data of the same healthy population is summarized in Table 2.2. Initial
studies were performed on a 21-year-old male morphometry with volumetric flow
rates varying between 10 and 30 L/min. Adult population studies included all
individuals between 14 and 21 over the same breath range and children population
studies included all individuals between 1 and 9 years old.

Table2.1: Demographic Information of the Sample Population [14]
Age (yr)

Gender

Weight (kg)

Height (cm)

BMI

0.25
1.75
1.92
2.33
3.00
8.67
9.42
14.00
14.08
18.00
21.00

F
M
M
F
F
M
M
F
F
M
M

5.9
9.0
9.1
12.2
13.6
26.0
40.9
51.0
56.0
52.0
67.0

66.0
71.1
94.0
94.5
109.0
118.0
143.0
175.2
147.0
135.0
177.8

13.5
17.8
10.3
13.7
11.4
18.7
20.0
16.6
25.9
28.5
21.2

Table 2.2: Healthy Physiological Data of the Sample Population [14]
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This data, however, was taken at total lung capacity (TLC) which is the absolute
maximum volume the lung can hold. During a normal breath, after exhalation the
lung is still inflated to a volume that is called the functional residual capacity (FRC).
Even iff you force all of the air out of your lung, there is still a residual volume which
remains, as can be seen below in Figure 2.2. The volume inhaled during a normal
breath cycle is called the tidal volume [15].. Since TLC is not the volume during a
normal breath, the data was scaled to be FRC + TV/2, or the volume of half of a full
breath. By taking the volume in the middle of the cycle, the average volume is being
used and the airway diameters from Ménache et al. (2008) can be adjusted
accordingly.

Figure 2.2: The Breath Cycle. This figure shows commonly used terminology
used to describe lung volumes.
(http://en.wikipedia.org/wiki/Function
http://en.wikipedia.org/wiki/Functional_residual_capacity
al_residual_capacity)
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The modeled breath cycle is important when making statements about deposition
in the lung. The breathing cycle consists of a series of peaks and plateaus where the
positive and negative slopes represent the inhale and exhale respectively. This model
assumes that all deposition occurs during inhalation and the flow rate is constant. It is
accurate to assume a constant flow rate because, as can be seen above in Figure 2.2,
the slope of the inhalation portion curve is constant, except for very small sections at
the beginning and end of inhalation, therefore flow rate is considered constant.
Deposition Calculation Code
Because variability in dosing can come from multiple sources, two codes were
developed in a computational software called MatLab which use the equations
discussed previously to calculate the volume of particles deposited from a
polydispersed spray in the last six generations of the lung.
Deposition over a Range of Flow Rates

The first code is used to optimize deposition for one lung morphometry over a
range of flow rates which will aid in the evaluation of the design space, the impaction
correlations, and the different distributions to be discussed later. It utilizes two nested
‘for’ loops to calculate the volume deposited for not just one volume flow rate, but for
an entire range . The inner loop calculates the number of particles deposited for a
particular diameter and stores the deposition information in a table. A study
performed by X.G. Cui showed that particles with diameters between 1.0 and 5.0 µm
contribute the least to deposition in the upper airways. Because of these results, his
study was used to evaluate the deposition of particles with a geometric particle
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diameter, d, from 1.0 µm to 7.0 µm in 0.2 µm increments. The increment was chosen
to be 0.2 µm so that data would have a refined resolution while remaining within a
realistic realm of control for particle generation. Lung morphometry data for the age
in question is read into this loop from a file, so the code can be easily altered to
calculate deposition for different lung models.
The outer loop changes the velocity of the flow and deposition for all of the
particle diameters is calculated again. An average, healthy adult breathes
approximately 13 L/min and a person with unhealthy lungs can get upwards of 25
L/min. For this reason, the range was chosen to be from 10 L/min to 30 L/min to
encompass the volumetric flow rate variability of the population. A study conducted
by Maarsingh et al. that monitored 0- to 3-year-old patients with asthma considered
breath rate to be normal at less than 40 breaths/min and severe asthma symptoms to
be present at greater than 60 breaths/min (Maarsingh,2005). Based on this
information, the infant study was performed for a flow rate range from 5 to 12 L/min
which would cover the normal, to severe asthmatic range. A range from 10 to 20
L/min was used for the 8- and 9-year-old because it is between the normal to severe
asthmatic range found for infants and adults.
The deposition data is stored in a table at the end of each iteration of the innerloop and at the completion of the outer-loop’s cycle, the volumes deposited of each
particle size are summed and the total deposition at each flow rate is determined. A
summary of the code can be found below in Figure 2.3.
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Figure 2.3: Flow Rate Variability Code Flow chart. This figure summarizes code written
to explore variability with respect to breath rates for the 21-year-old male using different
particle size distributions.
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Deposition over Different Lung Morphometries and Flow rates

The second code was written to explore the variability in deposition when both
flow rate and age/weight were taken into consideration. This will provide insight into
the variability across populations and will reveal whether or not deposition variability
can be improved using a particle size distribution optimization. In this code the
original code (Figure 2.3) is repeated four times to calculate deposition over the range
of flow rates for multiple age/weight lung morphometries (Figure 2.4). The flow chart
below (Figure 2.4) represents the optimization for the adult cohort which evaluates
the morphometry of a 21-year-old, 18-year-old, 14.08-year-old and 14-year old. This
code was also run for a child cohort containing the lung morphometries of people
between 1 and 9 years old and an adult cohort where the morphometries are adjusted
to approximate lung remodeling. Lung remodeling occurs in people who have had
severe asthma for many years that hasn’t been properly controlled. The remodeling
results in decreased airway diameters and also changes in lung elasticity. A paper by
Niimi et al. states that a 17% reduction in lung cross-sectional area is found in
patients with severe lung remodeling. In this study, only this change in the airway is
considered so the diameter of each airway was reduced by 42 percent to account for
the reduced cross-sectional area [16].
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Figure 2.4: Flow Rate and Lung Morphometry Code Flow Chart. This figure
summarizes the code written to explore variability with respect to body mass/age and
flow rate. The area highlighted in blue from Figure 2.3 is the flow rate loop referred
to in this figure.

Determining the Number of Particles of a Certain Size within a Distribution

Utilizing the codes described previously, the volume of particles deposited from a
polydispersed spray of a chosen distribution can be determined using the ‘pdf’
function in MatLab. This function’s output is the fraction of the total number of
particles that will be a certain diameter and its inputs are the distribution type,
distribution defining parameters, and the diameter of interest. It has the form
pdf(name, x, a, b) where ‘x’ is the particle diameter, ‘name’ is the distribution type
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and ‘a’ and ‘b’ are the defining parameters. For example, to determine the number of
particles that are 5 µm in diameter of a normal distribution with a mean of 3 µm and a
standard deviation of 1 µm, the function would be y=pdf(‘norm’,5,3,1) and the result
would be 0.242 meaning that out of 100 particles, 24.2 would have a diameter of 4
µm. When employed in a loop, and using the equation for NT, the number of particles
of each size in a controlled volume can be determined and used to compute
deposition. It can be seen below that the number of particles of each size, plotted as a
histogram (Figure 2.5, top), matches the plot of the distribution used (Figure 2.5,
bottom). So the ‘pdf’ function does, in fact, introduce the correct distribution to the
deposition model.
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Figure 2.5: Size Distribution Input and Output Data. The top figure is a histogram
of the number of particles calculated for the distribution within the code. The bottom
figure is the distribution plotted using the input mean, span and a lognormal pdf
function in MatLab.

Evaluated Distribution Types
Normal

Four distributions were selected to explore their effect on the reliability of dosing;
normal, lognormal, Weibull and bimodal. Normal distributions are defined by the
mean and standard deviation of the population and are symmetric about the mean, see
Figure 2.6 below. This distribution was chosen because is commonly used in a variety
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of applications and with a small enough standard deviation, it could also approximate
a monodisperse droplet stream.

Figure 2.6: Normal Distribution Behavior. This figure shows how the normal
distribution changes with its defining parameters, mean and standard deviation.
Lognormal

The lognormal distribution is characteristic of spray droplet size distributions and
is also defined by a mean and standard deviation and is skewed to favor smaller
particle sizes. Figure 2.7 illustrates how the lognormal mean and standard deviation
affect the shape of the distribution. The mean, µ, and standard deviation, σ, shown in
Figure 2.7 are the lognormal mean and standard deviation which are not to be
confused with the normal mean and standard deviation. An equation relating the
normal and lognormal parameter can be found below in where µ and σ are the normal
parameters and λ and ζ are their lognormal counterparts.
1
  lnμ  u
2

w
u  ln v1  & ( x
μ
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Figure 2.7: Lognormal Distribution Behavior. This figure shows how the lognormal
distribution changes with its defining parameters, the lognormal mean and the lognormal
span (standard deviation).

Weibull

A Weibull distribution can look like a normal or a lognormal distribution depending
on the values given to its defining parameters, the shape factor, k, and the scale
factor, λ. The scale factor can be likened to the mean and the shape factor controls the
skewed nature of the distribution. It can be seen in Figure 2.8 that at a larger k the
distribution begins to look like a normal distribution and at smaller k values it appears
to be more lognormal. This distribution, therefore, covers the middle ground between
the two distributions discussed previously.

33

Figure 2.8: Weibull Distribution Behavior. This figure shows how the Weibull
distribution changes with its defining parameters, scale factor and shape factor.
Bimodal

Finally, a bimodal distribution was considered. The bimodal distribution,
in this case, consists of two independent lognormal distributions defined by two
separate sets of means and standard deviations see Figure 2.9. This distribution was
chosen because the flexibility provided by the independent lognormal distributions
could make up for some of the variability in the deposition models.

Figure 2.9 Bimodal Distribution. This figure shows how a bimodal distribution is
composed of two lognormal distributions.
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Optimization Code
Background

As previously noted, deposition in the deep lung is dependent upon and critically
effected by numerous parameters, so when working in a complex design space such
as the lung it is often helpful to utilize optimization techniques to find the best
solution. Optimization methods take a function and either minimize or maximize it
using one or more variables. The variables being optimized start at an initial guess
and are changed by the applied algorithm within bounds set by the user. During the
initial steps, each of the variables is incremented individually to provide information
of sensitivity of a parameter and direction of the gradient. Once a few initial objective
functions are found via independent variable adjustment the optimization algorithm is
applied. Calculation of a gradient at each step allows the optimization routine to seek
out, in this case, the minimum. Typically large steps are taken when the gradient is
steep, smaller steps in locations where the gradient is reduced. Variable step length
improves the efficiency of the process, with little potential of stepping over the
minimum.
Optimization Function: fmincon

In this optimization, the MatLab function ‘fmincon’ was used. Fmincon is a
constrained, linear optimization code that searches for the minimum of a scalar
function by adjusting several variables beginning with an initial guess. The objective
of this study is to minimize the variability of deposition in the deep lung resulting
from the variability in patient physiology.
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The Objective Function

Variance, standard deviation and the coefficient of variation (COV) all describe
the dispersion of a data set, however, variance and standard deviation are both
functions of the mean so their values are not easily compared across data sets. [17]
For this reason, the dimensionless parameter COV was selected to be the minimizing
function. The COV is a ratio of the standard deviation and the mean (see below) and
as such is a normalized standard deviation. A smaller COV would indicate less
variability in the data and vice versa.
<%l 

w
?

By minimizing COV ‘fmincon’ seeks small standard deviations and large mean
depositions. In other words, the optimization is looking for a polydispersed spray that
minimizes the variation across the deposition data but also maximizes the total
volume deposited.

Constraint Options

Fmincon also offers a variety of constraint options including, but not limited to
setting bounds on the optimization variables. For this study, the optimization
variables are the defining parameters of the distribution being studied. The
distribution parameters and the bounds set on those parameters are summarized below
in Table 2.3.
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Table 2.3: Distribution Parameter Bounds. This table summarizes the boundaries
set on each distribution’s defining parameters. The variables x1, x2, etc. indicate that
they are separate parameters optimized by fmincon. Note: The means and standard
deviations are converted into microns within the code after the distribution has been
established.

Lognormal
Normal
Weibull
Bimodal
(Two Lognormal
Distibutions)

Variables
Mean (Normal)
Standard Deviation (Normal)
Mean
Standard Deviation
Scale Factor
Shape Factor
Mean (Normal)
Standard Deviation (Normal)
Mean (Normal)
Standard Deviation (Normal)
Weight

Bounds
1 ≤ x1 ≤ 7
0.6 ≤ x2 ≤ 3
1 ≤ x1 ≤ 7
0.6 ≤ x2 ≤ 3
1≤ x1 ≤ 7
1 ≤ x2 ≤ 2.5
1 ≤ x1 ≤ 7
0.6 ≤ x2 ≤ 3
1 ≤ x3 ≤ 7
0.6 ≤ x4 ≤ 3
0 ≤ x5 ≤ 1

It is also possible to control the optimization itself using the “optimset” option.
The default options can sometimes cause an optimization to terminate prematurely or
step over the minimum. For this reason, the options shown in Table 2.4 were utilized.
Table 2.4: Fmincon Optimization Parameters. This table summarizes some of the
key parameters set in fmincon for this optimization.
Name

Description
Termination tolerance on the function
TolFun
value
Termination tolerance on x, the
TolX
current point
Relative bound on line search step
RelLineSrchBnd
length.
Number of iterations for which the
RelLineSrchBndDuration
bound specified in
RelLineSrchBnd should be active.
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Set Value
1.00E-08
2.00E-08
1.00E-07
3.00E+03

CHAPTER THREE: RESULTS AND DISCUSSION
Before an “optimization” can be performed for the populations in question,
certain investigations need to be accomplished. First, relevant algorithms need to be
validated. Next, evaluations of simpler problems can reveal the behavior of systems and
aid in the setting of the optimization parameters as well as selection of deposition models.
Finally, populations can be evaluated and optimal distributions found and compared.

Validation of Optimization Code
The results of this study are founded upon the successful execution of the
optimization routine. To confirm that the optimization code works as it should, an
optimization was set up modeling deposition in a horizontally oriented tube with a bend.
The optimized parameter in this case was the angle, α, of the bend in the tube and the
minimizing function was the negative coefficient of variation (“COV”). Recall that the
COV is σ/µ, so by minimizing -COV the optimization should seek to increase the COV to
a point where the mean and standard deviation of deposition in the tube are equal, in
other words COV=1. This should occur when zero particles deposit and therefore
fmincon should optimize to a 0° bend angle which is a straight tube. The Cai and Yu
equation discussed in chapter 2 was used with a diameter ratio of 1 to calculate
deposition by impaction. The optimization was set up to vary the angle, α, from 0° to 90°.
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The initial and optimized angle and corresponding values for COV are summarized
below in table 3.1.
Table 3.1: Optimization Validation Results. The value X is the optimized variable which
is altered by fmincon to minimize the optimization function, COV.

The outcome of this effort demonstrates that the optimization utilized in this study
performs as expected and can be used to minimize the COV of deposition in the lung for
the remainder of this study.

Variability with Flow Rate Study (21-Year-Old)
It is important to examine flow rate first to understand the behavior of the system
under less complex conditions. This will aid in the selection of the impaction model.
Current Device Performance
To understand current inhaler aerosol performance, the particle size distributions of a
DPI and pMDI were recorded and the total volume of particles deposited in the last six
generations of the lung was calculated over the range of flow rates from 10 to 30 L/min.
These distributions are lognormal and can be seen below in Figure 3.1.
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Figure 3.1: Current pMDI and DPI Distributions.

This deposited volume was then plotted against the corresponding flow rate to
establish a baseline for the optimization, see Figure 3.2. From this plot, the sensitivity of
these aerosol delivery systems to flow rate was determined by fitting a linear trendline to
the data where the sensitivity is represented by the slope of the trendline. This was
performed for both CAI and Yu and Chan and Lippman equations so the differences
between the two impaction models can be highlighted.
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Figure 3.2: Fraction of delivered dose deposited in the deep lung as a function of flow
rate for current pMDI and DPI inhaler distributions. Top: Cai &Yu Correlation for
deposition by impaction. Bottom: Chan & Lippmann correlation for deposition by
impaction.

It becomes evident when comparing the two graphs above that the deposition
equations chosen have a significant impact on the deposition efficiency. The higher dose
deposited when using the Cai and Yu correlation (Figure 3.2, top) indicates that these
equations predict that fewer particles deposit in the upper generations and more reach the
deep lung when compared to the Chan and Lippmann equations. This aligns with the
validation performed in Chapter 2 where the Cai and Yu equation had much lower
deposition than Chan and Lippmann for higher stokes numbers. Having established a
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baseline it is now productive to explore the effect of mean and span on the COV for a
lognormal distribution.
The Design Space
Because particle diameter plays a major role in deposition it was hypothesized that
altering the mean and standard deviation of a distribution would change the coefficient of
variation (COV) and thus an optimization could be performed which minimized
variability with respect to flow rate and therefore improve deposition for a population. A
parametric study was undertaken to reveal the objective function value over the design
space using a lognormal distribution and to prove that the particle size distribution affects
COV.
The objective function of the lognormal spray distribution was evaluated using the
Cai & Yu impaction equations over a range of mean 1 to 7 µm, span 0.6 to3 µm resulting
in a COV value between 0.135 and 1.0. The figure below (Figure 3.3) exposes some of
the data from that study and proves that the mean and standard deviation do affect the
COV. It also indicates that a minimum, represented by the color purple, exists that can be
sought by an optimization process. It is important to note that the entire design space
evaluated is not presented in this figure so the existence of a plateau can be revealed more
clearly. Plateaus occur when the steps taken by the optimization result in changes to the
objective function within the function tolerance. In other words the objective function
(COV) does not change enough to justify continuing the optimization. These plateaus
can result in a premature termination of the optimization routine. Therefore, to ensure the
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discovery of a global minimum, all optimizations were performed from various initial
conditions.

Figure 3.3: Design space for a lognormal distribution using the Cai and Yu
correlation

The Optimization
In addition to collecting more comprehensive data, it is important to explore the
potential of different types of particle size distributions and to select an impaction
correlation equation, therefore, an optimization was performed using the 21-year-old lung
morphometry over a range of flow rates from 10 to 30 L/min in 1 L/min increments. This
optimization of COV was run for four distributions of interest (normal, lognormal,
bimodal, Weibull) and was compared to the baseline performance found previously in
Section 1. The results are summarized in Table 3.2 below.
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Table 3.2: Flow Rate Only Optimization Results. The mean and span of the lognormal
distribution is the equivalent normal mean and span (see the methods chapter for the
relationship). The weight associated with the first and second mean-span is the fraction of
therapeutic designated to the corresponding peak.)
Cai and Yu Impaction Correlation
Distribution
Type

Mean
1

Distribution Properties
Span Weight Mean Span
1
1
2
2

pMDI

1.57

0.83

-

-

-

-

DPI

1.36

0.73

-

-

-

-

Normal

3.30

0.60

-

-

-

-

Lognormal

3.10

0.60

-

-

-

-

Weibull

2.60

2.50

-

-

-

-

Bimodal

3.16

0.60

0.64

2.95

0.62

0.36

Weight
2

Optimization Results
Dep.
St.
COV
Eff.
Dev.
4.48
21.78%
0.17
E-09
4.59
22.83%
0.17
E-09
6.09
37.79%
0.13
E-09
6.22
38.34%
0.14
E-09
6.35
37.76%
0.14
E-09
6.30
38.74%
0.14
E-09

Chan and Lippmann Impaction Correlation
Distribution
Type

Mean
1

Distribution Properties
Span Weight Mean Span
1
1
2
2

pMDI

1.57

0.83

-

-

-

-

DPI

1.36

0.73

-

-

-

-

Normal

1.00

0.60

-

-

-

-

Lognormal

1.33

0.60

-

-

-

-

Weibull

1.00

1.95

-

-

-

-

Bimodal

1.40

0.98

0

1.21

0.6

0.02

Weight
2

Optimization Results
Dep.
St.
COV
Eff.
Dev.
5.32
11.42%
0.39
E-09
5.10
10.50%
0.41
E-09
8.39
32.54%
0.22
E-09
8.02
29.26%
0.23
E-09
8.35
33.19%
0.21
E-09
8.09
29.70%
0.23
E-09

Similar values for COV were obtained for all optimized distributions within the same
impaction correlation data set. By performing an optimization, a significant improvement
was made to COV with respect to the current PDI and MDI inhalers. This improvement
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in COV was much less using the Cai and Yu equation than the Chan and Lippmann,
however, the initial value of the COV was much lower for the Cai and Yu equation than
it was for Chan and Lippmann. This discrepancy in COV can be explained by the
predictive behaviors of the respective correlations. Recall that the Cai and Yu equation
predicts much higher deposition efficiency in the lower airways (Figure 3.2) and in
Chapter 2 the coefficient of variation was defined as the standard deviation divided by the
mean. It can be seen in Table 3.2 that the standard deviations for both correlations are
close, so the difference in COV must be driven by the denominator, the mean deposition.
Because the mean deposition is considerably higher for the Cai and Yu case from the
beginning, the resulting change in COV is much less than that for Chan and Lippmann.
With this in mind, coefficients of variation from the four optimized distributions using
the Chan and Lippmann impaction model were approximately half of the current
distributions injected by commercial atomizer, where Cai and Yu COVs were only
reduced by a couple percent. In both cases deposition efficiency improved by 20%, from
~10% to ~30% for the Chan and Lippmann equation and from ~20% to ~40% for the Cai
and Yu equation.
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Figure 3.4: Optimized Distributions for Chan & Lippmann Impaction

The Chan and Lippmann distributions for the lognormal, normal and the bimodal
are nearly identical (Figure 3.4). In Table 3.2 it can be seen that the bimodal distribution
optimized to one mode; the optimization put all of the therapeutic in one peak via the
weighting. Only the Weibull distribution falls slightly away from the rest with a mode or
peak particle diameter of closer to zero, and a span near 1 µm, which is difficult to
physically generate.

Because of this similar shape in delivered particle size, the

minimum COV value has a variation close to the convergence limit for the algorithm
applied, thus all distributions should be considered identical in performance.
These distributions have a mode very similar to that currently delivered by DPI and
pMDI devices (Figure 3.1). The span, however, is dramatically smaller indicating a need
for a more controlled spray.
The polydispersity index is commonly used in industry to discern whether or not a
distribution can be considered monodisperse. The polydispersity index specifies
46

distributions as monodisperse when the index is less than 1.2. This index is the mean by
volume of the distribution divided by the mean by number. The index for the optimized
distributions close 1.04, which is well below the threshold, therefore the optimized
distribution can be considered highly monodisperse.

Figure 3.5: Optimized Distributions for Cai & Yu Impaction.

Notice that the optimized distributions with Cai and Yu are also identical (Figure
3.5), with the exception of the Weibull peak. The Weibull distribution had a mode below
2 µm and a significantly larger span. Although the minimum COV for Weibull is only
0.21 compared to 0.22 for the others, it is outside the convergence tolerance limits of the
optimization. Figure 3.5 also shows that although the weight is shared between the
bimodal distribution peaks (Table 3.2), the bimodal peaks are on top of one another, so
the distribution, like for Chan and Lippman, can be considered single valued. The Cai
and Yu impaction correlation’s optimized distributions are different from those of Chan
and Lippmann and current devices having a higher mean by nearly 1.5 µm. The
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polydispersity index for the Cai and Yu distributions is approximately 1.04 as well and
therefore the distributions optimized with the Cai and Yu deposition equation are also
monodisperse.
To quantify improvement over current devices, the optimized deposition data of the
distributions were then compared to the MDI data as can be seen below in Figure 3.6.
Although the slopes of the lines in Figure 3.6 indicate a dependence on flow rate, the
slopes are not what this study seeks to minimize. As discussed in Chapter 2, the
coefficient of variation is the minimizing function and the slope represents the standard
deviation which is the numerator of COV. The standard deviation is normalized by the
mean in the denominator. By optimizing in this way, the degree of dispersion from the
mean is minimized rather than just the standard deviation itself. The standard deviation
on its own speaks little of the actual variation because it is a function of the mean. For
example, a population with a mean of 100 and a standard deviation of 25 actually has the
same degree of dispersion as a population with a mean of 10 and a standard deviation of
2.5, despite the drastically different standard deviations [Halder, 2000]. Neither the Chan
and Lippmann nor the Cai and Yu optimizations reduce the slopes notably with respect to
the baseline DPI slope (Figure 3.6), but they both improved the degree of dispersion from
the mean by increasing deposition while holding the standard deviation relatively
constant.
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Figure 3.6: Fraction of delivered dose deposited in the deep lung as a function of flow
rate for tested distributions. Top: Cai &Yu Correlation for deposition by impaction.

The study conducted by Zanen et al., discussed in Chapter 1, found that particles with
2.8 µm diameters deposited better to provide a higher therapeutic effect than both 1 and 5
µm. For this reason, the Cai and Yi correlation was chosen to do the remainder of this
study for deposition by impaction as it predicts an optimum closest to that found in
clinical studies. Furthermore, due to the fact that all distributions behave similarly, the
log normal and bimodal distributions were selected for the following optimizations.
These distributions were selected because lognormal distributions are used in current
commercial devices so incorporation of new distribution characteristics would be simple.
In addition the second distribution could potentially improve deposition variation across
populations.
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Age/Weight and Flow Rate Variability Study
Optimization for Adults Only
With an impaction correlation and particle size distributions selected, an
optimization seeking improved variability and deposition across populations can be
examined. In this section, variability in an adult cohort consisting of 21-, 18-, 14.08- and
14 year-old lung cast data was analyzed over the same range of flow rates discussed in
the previous section. When lung morphology as a result of an individual’s mass, was
added into the optimization function, the COV increased by 3 times what it was when
only flow rate variability was considered. Under the conditions in this study, a variability
of over 60% was observed in the pMDI /DPI performance. This is not surprising given
the strong role lung morphometry plays in deposition; the introduction of variability to a
critical parameter will increase the variability of the whole system. This increase in COV
would explain the large variability observed in clinical settings. Although researchers
have recognized physiology as a problem, most have downplayed its significance instead
focusing only on variables that can be controlled like angle of injection etc.
It was predicted that a significant improvement to deposition and variability could be
achieved by employing an optimization strategy to the injected aerosol plume. In
complex design spaces where both controllable and uncontrollable variables exist, a
combination of design innovations can be used to manipulate the controllable variables to
near optimal conditions and tune manufacturing tolerances to minimize the impact of
uncontrollable variables. However, it can be seen in Figure 3.7 that increasing the system
complexity to include a range of adults did not shift the new optimized distribution far
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from the flow-rate-only optimization above (only about 0.5 µm) and the optimized spray
is still monodispersed.

Figure 3.7: Optimized Bimodal and Lognormal Distributions. Top left: Bimodal 2. Top
right: Bimodal 1. Bottom: Lognormal.

The summary of the optimizations can be seen in Table 3.3. Only a small
improvement in the COV is observed (<2%). Although this satisfies the convergence
criteria of the optimization, it does not appear to improve variable clinical outcomes at
least in a measureable quantity. Moreover, there appears to be a slight tradeoff between
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deposition efficiency and standard deviation. In all optimizations the mean volume of
particles deposited across lung morphometry and flow rates is increased substantially,
while the standard deviation is increased slightly. While this still greatly improves the
deposition across a population, it was anticipated. The expected result was a wide
distribution that would decrease standard deviation, perhaps to the detriment of volume
deposited. Instead, like in the previous section, the optimization seeks to reduce the COV
by increasing overall deposition (a 10% rise is observed which may be desirable) rather
than reducing the standard deviation. This could be a result of a relatively small sample
size that includes markedly different lung geometries which makes altering the standard
deviation of deposition difficult because the mean deposition in each lung model is so
different to begin with. The optimization searches for the best way to minimize the
objective function, COV, and in this case, increasing the deposition efficiency across the
geometries is the most effective.
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Table 3.3: Flow Rate and Mass Optimization Results. The mean and span of the
lognormal distribution is the equivalent normal mean and span (see methods chapter).
Not all runs are represented in this table. The table summarizes the most interesting
results from the optimization to demonstrate the potential of all distributions.

Distribution
Type

Mea
n1

Cai and Yu Impaction Correlation
Distribution Properties
Span Weigh Mea Span Weigh
1
t1
n2
2
t2

pMDI

1.57

0.83

-

-

-

-

DPI

1.36

0.73

-

-

-

-

3.60

0.60

-

-

-

-

1.56

1.11

0.39

3.93

0.6

0.61

3.53

0.60

1.00

-

-

-

Optimized
Lognormal
Optimized
Bimodal 1
Optimized
Bimodal 2

Optimization Results
Dep.
St.
COV
Eff.
Dev.
1.72E 0.63
23%
-08
7
1.66E 0.63
22%
-08
9
2.42E 0.62
32%
-08
1
2.36E 0.62
31%
-08
7
2.50E 0.62
33%
-08
6

Another interesting outcome of this study pertains to the two different types of
distributions evaluated. While the lognormal case optimized to the same distribution
when initialized from different places, the bimodal distribution optimized to different
locations maintaining the same coefficient of variation. This indicates that there is a
plateau in which different combinations of lognormal distributions can yield the same
COV. In some cases the bimodal optimization the distribution did not remain bimodal; it
converged to a single mode with the same optimized parameters as the lognormal
distribution (Bimodal 2, Figure 3.7). It did this by either putting all of the weight in a
single peak or by shifting both peaks to be in the same location. The addition of the
second peak (Bimodal 1, Figure 3.7) reduced the standard deviation with respect to the
other optimizations while maintaining the same deposition efficiency. This is exactly
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what was hypothesized for the second peak, however, as shown in Table 3.3 and Figure
3.7, the second peak includes a large amount of particles less than one micron in
diameter. Studies show that particles that small are often exhaled and do not actually
deposit in the lung. A deeper exploration of this plateau region and the convergence
criteria of the objective function could reveal a more realistic bimodal optimum.
This optimization improved the mean deposition efficiency of an adult cohort
from ~22% in current devices to ~32%. Consequently the coefficient of variation of
deposition across morphometry and flow rate was also improved. The resulting
distributions and population deposition information can now be compared, to those of
outlier populations.
Optimization for Adults with Lung Remodeling
An optimization was performed on the adult cohort consisting of 21-, 18-, 14.08- and 14year-old lung models, like in the previous section, with an adjustment made to their
airway diameters to simulate the remodeling which occurs in the lung after many years of
having severe asthma. These optimization results were then compared to those of the
healthy adults below in Table 3.4.
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Table 3.4: Optimization Results for a Sample of Healthy and Remodeled lungs
Healthy Adults
Distribution Properties
Optimization Results
Distribution Type
Mean 1
Span 1
Dep. Eff. St. Dev. COV
pMDI
1.57
0.83
22.56% 1.72E-08 0.637
DPI
1.36
0.73
21.68% 1.66E-08 0.639
Optimized Lognormal
3.60
0.60
32.45% 2.42E-08 0.621
Unhealthy Adults (Remodeling)
Distribution Properties
Optimization Results
Distribution Type
Mean 1
Span 1
Dep. Eff. St. Dev. COV
pMDI
1.57
0.83
11.00% 9.15E-09 0.693
DPI
1.36
0.73
10.05% 8.50E-09 0.705
Optimized Lognormal
2.78
0.60
31.93% 2.40E-08 0.626

The deposition efficiency for both the healthy and remodeled lung models were
increased. The optimization of the injected spray for lungs with severe remodeling
decreased the coefficient of variation from 0.7 to almost 0.6 despite the slight
increase in standard deviation by tripling the depostion efficiency.

The healthy

optimization only decreased the COV from 0.63 to 0.62, however the improvement in
depsosition was significant, as discussed in the previous section. The deposition in the
healthy and remodeled lungs were improved by approximately 15 and 35 percent
respectively. The resulting optimized distributions can be seen below in Figure 3.8
where the means of optimal distributions for the healthy and remodeled lung differed
by approximately one micrometer. It is important to note that the airway diameters
were adjusted in accordance with remodeling data therefore the changes to lung
elasticity were not captured. A FSI (Fluid, Solid Interaction) computational model
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would need to be developed to more accurately capture the deposition behavior in the
lungs of severe asthmatics.

Figure 3.8: Optimized Distribtions for Healthy and Remodeled Lung Morphometries.
The optimized lognormal size distribution for an adult cohort of remodelled lungs can
be seen on the left and the optimized lognormal size distributionfor the same adult
cohort without lung remodelling can be seen on the right.
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Figure 3.9: Deposition Efficiency as a Function of Flow Rate in Healthy and
Unhealthy 21-year-old Lung Models.
56

It can be seen above in the Figure 3.9, which represents the deposition in the 21year-old lung model, that any increase in slope that resulted from the optimization is
slight compared to the increase in deposition. In this adult population the sensitivity
to velcocity is less critical than it would be in younger pateients due to the increased
liklihood of overdose in children and infants. This most important thing to notice
from this optimization which can be most easily seen in Figure 3.9 is that by
optimizing the particle size distribution for the remodeled lung morphometry, those
adults who suffer from athsma induced remodeling are taken from receiving almost
no therapeutic at all to receiving the same amount of dose as the healthy adults.
It is important to note here that an optimization encompassing both healthy and
remodeled lungs was attempted but the optimized distribution didn’t change from that
of the healthy adult. This is most likely due to the fact that the respective optimal
distributions are so close to one another; differing by only one micrometer. However,
as demonstrated above, a different injector for severe asthmatics would provide
significant improvement from existing technologies.
Optimization for Children
To explore optimization for yet another outlying population, the optimization
performed for the adults was also compared to one of children younger than ten where
lung cast data from a 1.75-, 1.92, 2.33 and a 3-year-old were used. Each age group, adults
and children, was optimized twice; once with the COV as the objective function and
again with standard deviation as the objective function to see how the optimization would
behave. The results from the optimizations are summarized in Table 3.5.
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Table 3.5: Summary of Adult and Children Cohorts Optimization
Adult Lognormal Optimization
Distribution Properties
Optimization Results
Optimized Function
Mean 1
Span 1 COV Dep. Eff. St. Dev.
pMDI
1.36
0.73
0.64 22.56% 1.72E-08
DPI
1.57
0.83
0.63 21.98% 1.66E-08
COV
3.63
0.60
0.63 33.24% 2.50E-08
Standard Deviation
1.00
3.00
0.63 24.89% 1.90E-08
Children Lognormal Optimization
Distribution Properties
Optimization Results
Optimized Function
Mean 1
Span 1 COV Dep. Eff. St. Dev.
pMDI
1.36
0.73
1.09
2.00% 2.60E-09
DPI
1.57
0.83
1.12
1.85% 2.49E-09
COV
1.20
0.60
0.68
5.10% 4.19E-09
Standard Deviation
7.00
0.60
1.95
0.54% 1.25E-09

When the objective function was the standard deviation, the optimization ran to the
boundaries where there is zero deposition. It can be seen in Figure 3.10 that a 3-year-old
receives close to zero therapeutic with the distribution suggested by the optimization with
the standard deviation as the objective function. This low deposition would be even
worse in infants so there is even less room to sacrifice deposition for less variability.
This, coupled with the optimization going to the boundary, concludes that optimizing the
standard deviation in this way is not useful especially for children whose deposition
efficiency is already extremely low. The adult standard deviation shows that there is 25%
deposition efficiency for a mean of one micrometer but, as discussed earlier, particles
with diameters less than one micrometer tend to be exhaled so the deposition efficiency is
likely much less than indicated here.
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Figure 3.10: Deposition Efficiency as a Function of Flow Rate for a 21- and 3-yearold.

When the COV was used as the optimization function, significant improvement was
made in the children cohort. The mean deposition efficiency was increased from 2% to
5% and the COV was reduced to 0.68 from over one. This is significant if you look at
Figure 3.10 and consider the deposition for the 3-year-old. The pMDI distribution yields
almost no deposition, and therefore a chance of no therapeutic effect at the higher flow
rates. However, the optimized distributions yielded around 5 percent. This could mean
the difference between life and death for a sick infant.
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Figure 3.8: Optimized Lognormal Paticle Size Distribtions for Children and Adult
lung Morphometries. Left: children cohort. Right: adult cohort
With optimized distributions more than 2 microns apart (Figure 3.11), it was
hypothesized that a dual-nozzle spray could be used that would satisfy both the adult and
children cohorts. However, when the optimization was run with the adults and children
together, the optimization algorithm went to the boundary. This is because the mean
depositions of the two cohorts are so far apart (Figure 3.10). The optimization routine
tries to bring the mean deposition closer together to reduce the COV but because of the
vastly different geometries it cannot. So it optimizes to the boundaries where there is zero
deposition just like it did for the optimizations using the standard deviation as the
objective function.
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This optimization proves that one size distribution cannot work for all users and also
suggests that an inhaler with two or more nozzles with different distributions can
potentially be utilized to successfully dose the population. That being said, if one device
with multiple nozzles is to be implemented, a study exploring the effects on deposition of
each nozzle on all of the populations would need to be conducted to prevent overdosing,
especially in children.
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CHAPTER FOUR: CONCLUSION
This analysis revealed that the Cai and Yu impaction model provided more
clinically relevant deposition results in the deep lung for the techniques employed. It also
exposed the criticality of choosing the correct empirically derived deposition model, to
understanding the results of optimization.

Additionally, fluid-solid interaction (FSI)

modeling is necessary to eradicate errors inherent in empirical models.
In this instance, a lognormal distribution was used to optimize deposition
coefficient of variation in the last six generations of the lung for a range of ages and flow
rates which represent the variability in lung morphometry as a function of mass and
health state. The normal, bimodal and Weibull distributions were also tested, but
performance was the same across distributions. It should be noted, however, that there is
potential for control of the standard deviation of deposition using a bimodal distribution.
But further investigation of the objective function tolerance and the possible bimodal
combinations is required.
Minimizing the standard deviation did not result in a realistic optimization of the
particle size distribution. The optimization seeks zero deposition to minimize the standard
deviation and, as a result, the final distribution is at the bounds of the routine. This is
undesirable because no therapeutic is actually delivered and unrealistic because studies
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show that particles larger than seven micron or smaller than one micron either do not
make it into the lower regions of the lung or are exhaled. Consequently, not much can be
done to improve the standard deviation of the population deposition efficiency using a
single-peak distribution without drastically reducing the mean volume deposited. This is
most likely a result of the study’s small sample size or too great of a variation in
deposition could be too great for the optimization to work properly. A reduction in
deposition could be acceptable in adult population where efficiency is greater, but in
infants deposition efficiency is already extremely low, ~5%. Therefore, a reduction could
result in no therapeutic delivered at all. Unfortunately, low variability is also more critical
in younger patients due to the stronger threat of overdose. More research is needed to
effectively and safely treat these patients using inhaled aerosols.
In a population consisting of four healthy, adult lung models the mean deposition
efficiency over the range of flow rates 10 to 30 L/min was improved from ~20% to ~30%
when employing a monodisperse spray of 3.6 µm compared to current inhaler devices.
An adult cohort population with severe lung remodeling over the same range of flow
rates was also optimized. The resulting lognormal distribution improved deposition
efficiency from ~10% to ~30% and the COV was reduced from ~0.7 to 0.62. It is
important to emphasize that by optimizing the distribution the remodeled cohort took
them from having little to no deposition from current devices to having the same
deposition as the healthy cohort. This was achieved using a monodisperse spray of
diameter 2.8 µm which suggests that having specialized particle distributions for this
population might have measurable clinical impacts. Even when the changes in lung
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elasticity are ignored, vast shifts in deposition and subsequently the optimal particle size
distribution are evident. Lung remodeling, although not completely modeled in this study,
should not be ignored in future work. Here FSI (fluid-solid interaction) modeling would
need to be employed to accurately characterize the behavior of the diseased lung.
In a children cohort consisting of a 1.75-, 1.92-, 2.33- and a 3-year-old, mean
deposition efficiency was improved from ~2% to ~5% and the COV was reduced from
~1 to ~0.68 when a monodisperse spray of 1.2 µm diameter particles was used. This
improvement in mean deposition efficiency brings the deposition at higher flow rates
from being at or near zero to somewhere between 5% and 10%. Current inhalers have
little to no efficacy at higher flow rates, so for a crying infant or one suffering an asthma
attack, both of which result in increased flow rates, this extra 5% deposition efficiency
could mean life or death.
The vast difference between adults and children in deposition suggests that a
single device that outputs a single particle size for both populations is not advised. A
multi-node distribution could, in fact, reduce the large variation in the mean deposition
without sacrificing efficiency. Bimodal optimization were run for the adult cohort over a
range flow rates from 10-30 L/min and the resulting distribution was dependent on the
initial conditions and the convergence criteria of the optimization. Different combinations
of two peaks resulted in the same COV with different mean deposition volumes and
standard deviations. This is exactly what was hypothesized in the introduction; a
combination of distributions can reduce the variation in deposition across a population.
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Further investigation of this plateau could reveal that a combination of distributions
emanating from two or more nozzles on a device can improve device reliability and
efficacy over a larger population of patients.
Important future work would be to further investigate the design space where
there are plateaus in COV to see how much multi-node distributions can improve device
reliability. This would benefit from an increase in the sample size so more lung cast data
should be analyzed to properly represent the population. A multi-modal investigation of
deposition overlap should also be considered so that overdosing, especially of children,
can be avoided.
Advances in computation could boost follow on studies. A pattern search
algorithm could be used to seek out a global minimum as opposed to running the
optimization from many different initial conditions. Also, more advanced computational
methods could be employed, such as FSI modeling, to account for inaccuracies in current
statistical and empirical lung deposition models. It would even improve understanding in
the areas of lung remodeling and lung elasticity.
In sum, the complexities of the multiple variables that complicate optimal aerosol
deposition in the lungs would greatly benefit from computational advances applied to
larger sample sizes, advanced FSI type modeling, and multi-modal devices.
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APPENDIX A: LUNG MORPHOMETRY DATA
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